

Resource Summary Report

Generated by [dkNET](#) on Sep 4, 2026

CD14 Antibody, anti-human, VioGreen™, REAfinity™

RRID:AB_2655057

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-110-525, RRID:AB_2655057

Antibody Information

URL: http://antibodyregistry.org/AB_2655057

Proper Citation: Miltenyi Biotec Cat# 130-110-525, RRID:AB_2655057

Target Antigen: CD14

Host Organism: human

Clonality: monoclonal

Comments: Applications: MACS Flow Cytometry
Antigen Distribution: monocytes, macrophages, spleen

Antibody Name: CD14 Antibody, anti-human, VioGreen™, REAfinity™

Description: This monoclonal targets CD14

Target Organism: human

Clone ID: clone REA599

Antibody ID: AB_2655057

Vendor: Miltenyi Biotec

Catalog Number: 130-110-525

Record Creation Time: 20231110T034437+0000

Record Last Update: 20260829T161647+0000

Ratings and Alerts

No rating or validation information has been found for CD14 Antibody, anti-human, VioGreen™, REAfinity™.

No alerts have been found for CD14 Antibody, anti-human, VioGreen™, REAfinity™.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Saggau C, et al. (2024) Autoantigen-specific CD4+ T cells acquire an exhausted phenotype and persist in human antigen-specific autoimmune diseases. *Immunity*, 57(10), 2416.

Li H, et al. (2023) Abundant binary promoter switches in lineage-determining transcription factors indicate a digital component of cell fate determination. *Cell reports*, 42(11), 113454.

Zeng S, et al. (2023) Candida albicans-specific Th17 cell-mediated response contributes to alcohol-associated liver disease. *Cell host & microbe*, 31(3), 389.

Saggau C, et al. (2022) The pre-exposure SARS-CoV-2-specific T cell repertoire determines the quality of the immune response to vaccination. *Immunity*, 55(10), 1924.

Krämer B, et al. (2021) Early IFN- γ signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19. *Immunity*, 54(11), 2650.

Bacher P, et al. (2020) Low-Avidity CD4+ T Cell Responses to SARS-CoV-2 in Unexposed Individuals and Humans with Severe COVID-19. *Immunity*, 53(6), 1258.